The Department of Health & Social Care has published a series of Guidance documents, aiming to inform the pharmaceutical industry on how to prepare for a no-deal Brexit scenario. The details will be published in MAP Online Legal section dedicated to Brexit in due course.
A number of stakeholders commented on the Guidance notes, including Nuffield Trust and Royal College of Physicians (RCP). According to Mark Dayan, policy analyst at the Nuffield Trust, “it has been said that no deal is better than a bad deal. But in the case of the NHS, any deal we are likely to get is better than no deal at all.” He added that whilst the Government’s step was understandable, the prime focus should be on avoiding a no-deal scenario, which would mean uncertainty for the manufacturers and the NHS in terms of supplies and storage facilities, impeding access to patient care. Both Nuffield Trust and RCP also expressed concern about possible staff shortages if the immigration policy is not made clear.
The technical notes can be found here:
It is worth noting that the Guidance information provided by the Government is not binding for the companies, which remain free to decide how they wish to prepare for Brexit.